Amin and colleagues have attempted to estimate the cost savings to the US health-care system if drug-eluting coronary stents were more selectively used in patients at low risk of restenosis. Their results and conclusions raise statistical, societal, and ethical issues that need to be considered before this approach should be widely embraced.
Matthew A Cavender, Stephen G Ellis. Stent choice and the hidden consequences of cost savings. Nature reviews. Cardiology. 2012 Oct;9(10):559-60
PMID: 22922596
View Full Text